Alumis Inc. Common Stock(ALMS)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Alumis faces a precarious financial outlook as its reliance on erratic milestone payments, which plummeted to $1.7 million in 2026Q1, fails to offset the massive R&D expenditures that reached $108.8 million in 2025Q2.
• The company's structural dependence on external funding is underscored by a $994.9 million accumulated deficit, which severely impairs equity quality and limits strategic flexibility.
• Investors should monitor the rapid depletion of cash reserves, which fell from $213.4 million in 2024Q3 to $63.9 million in 2026Q1, as the firm struggles to sustain its late-stage clinical pipeline.